Biohaven Pharma (BHVN)
15.69
-0.17 (1.07%)
Upcoming Events
Latest Headlines
Canaccord Reiterates Buy Rating on Biohaven Pharma (BHVN)
August 28, 2026 8:10 AM - StreetInsider
H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharma (BHVN)
August 27, 2026 7:07 AM - StreetInsider
TD Cowen Reiterates Buy Rating on Biohaven Pharma (BHVN)
August 26, 2026 11:01 AM - StreetInsider
Biohaven Pharma (BHVN) PT Lowered to $30 at Raymond James
August 26, 2026 10:17 AM - StreetInsider
Biohaven licenses Kv7 epilepsy platform to SK Biopharma for up to $795M
August 26, 2026 7:05 AM - StreetInsider
Form 8-K Biohaven Ltd. For: Aug 26
August 26, 2026 6:39 AM - SEC Filing
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
August 26, 2026 2:37 AM - PR NewsWire
Court awards Biohaven and Yale $4M in trade secret case
August 25, 2026 4:44 PM - StreetInsider
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale
August 25, 2026 4:42 PM - PR NewsWire
Form 3 Biohaven Ltd. For: Aug 06 Filed by: Yetimoglu John
August 14, 2026 6:01 PM - SEC Filing
Form SCHEDULE 13G Biohaven Ltd. Filed by: Woodline Partners LP
August 14, 2026 11:01 AM - SEC Filing
Biohaven Pharma (BHVN) PT Raised to $19 at Morgan Stanley
August 12, 2026 8:11 AM - StreetInsider
Biohaven Pharma (BHVN) PT Raised to $23 at RBC Capital
August 11, 2026 7:57 AM - StreetInsider
Biohaven Pharma (BHVN) Misses Q2 EPS by 3c
August 10, 2026 4:24 PM - StreetInsider
Form 8-K Biohaven Ltd. For: Aug 10
August 10, 2026 4:23 PM - SEC Filing
Form 10-Q Biohaven Ltd. For: Jun 30
August 10, 2026 4:21 PM - SEC Filing
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
August 10, 2026 4:02 PM - PR NewsWire
Form 8-K Biohaven Ltd. For: Aug 03
August 7, 2026 4:12 PM - SEC Filing
Biohaven adds AI investor John Yetimoglu to its board
August 6, 2026 7:00 AM - StreetInsider
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
August 6, 2026 7:00 AM - PR NewsWire
Jury awards Biohaven and Yale $4M in trade secret case
July 27, 2026 7:01 AM - StreetInsider
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million
July 27, 2026 7:00 AM - PR NewsWire
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
July 20, 2026 7:30 AM - PR NewsWire
Form 3 Biohaven Ltd. For: Jul 09 Filed by: Volles Warren Karl
July 17, 2026 6:00 PM - SEC Filing
Form 8-K Biohaven Ltd. For: Jul 09
July 9, 2026 5:11 PM - SEC Filing
Biohaven names new discovery head as CSO shifts to part-time role
July 9, 2026 5:01 PM - StreetInsider
Biohaven Announces Scientific Leadership Transitions
July 9, 2026 5:00 PM - PR NewsWire
Form SCHEDULE 13G/A Biohaven Ltd. Filed by: Janus Henderson Group Ltd.
July 8, 2026 5:44 PM - SEC Filing
Biohaven completes enrollment in focal epilepsy drug trial
June 30, 2026 7:31 AM - StreetInsider
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
June 30, 2026 7:30 AM - PR NewsWire
Biohaven Pharma (BHVN) call put ratio 7.5 calls to 1 put as share price down 4.7%
June 29, 2026 3:27 PM - StreetInsider
BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns
June 29, 2026 11:51 AM - StreetInsider
Biohaven starts Phase 3 trial of BHV-1300 for Graves' disease
June 29, 2026 7:31 AM - StreetInsider
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
June 29, 2026 7:30 AM - PR NewsWire
BofA Securities Downgrades Biohaven Pharma (BHVN) to Underperform
June 29, 2026 6:10 AM - StreetInsider
Biohaven Pharma (BHVN) PT Raised to $20 at Deutsche Bank
June 26, 2026 7:11 AM - StreetInsider
Increasing unusual option volume: BHVN DOMO CLPT OIH CVLT PEGA OTLK VT
June 17, 2026 10:15 AM - StreetInsider
Full Article List
